and have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer鈥檚 and Parkinson鈥檚 diseases.
The partners will work on ST-501 for tauopathies, such as Alzheimer鈥檚 and ST-502 for synucleinopathies, such as Parkinson鈥檚 disease.
In addition to a third undisclosed neuromuscular disease target, the companies will develop nine other neurological disease targets.
To alter gene expression, Sangamo鈥檚 zinc finger protein (ZFP) technology will be in use.
Biogen Research and Development executive vice-president Alfred Sandrock said: 鈥淎s a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance.
鈥淲e aim to develop and advance these programmes forward to investigational new drug applications.鈥�
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSangamo鈥檚 ZFP technology is delivered using adeno-associated virus and functions at the DNA level. It works by accurately repressing or activating the expression of specific genes.
In preclinical studies, ST-501 and ST-502 showed specific, potent and tunable tau and repression when delivered with AAV vectors.
The deal provides Biogen with sole worldwide rights to ST-501 for tauopathies, ST-502 for synucleinopathies and a third undisclosed neuromuscular disease target.
Biogen holds exclusive rights to propose up to nine additional undisclosed targets over five years.
Sangamo will be responsible for early research activities, with costs shared by the companies. The research will focus on the development of the combination of CNS delivery vectors and ZFP-TFs that target therapeutically relevant genes.
Biogen will carry out all further research activities and fund the investigational new drug-enabling studies, clinical development, regulatory undertakings and commercialisation worldwide.
Under the terms of the alliance, Biogen will pay $350m to Sangamo at the closing of the deal.
Sangamo is also eligible for up to $2.37bn in development, regulatory and commercial milestones, including up to $925m in pre-approval milestones and up to $1,445m in the first business sale and additional sales-based discoveries.
